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Abstract
Background: Pathogenic mutations in FBN1, encoding the glycoprotein, fibrillin-1, cause Marfan syndrome (MFS)
and related connective tissue disorders. In the present study, qualitative and quantitative effects of 16 mutations,
identified in FBN1 in MFS patients with systematically described phenotypes, were investigated in vitro.
Methods: Qualitative analysis was performed with reverse transcription-PCR (RT-PCR) and gel electrophoresis, and
quantitative analysis to determine the FBN1 mRNA levels in fibroblasts from the 16 patients with MFS was performed
with real-time PCR.
Results: Qualitative analysis documented that the mutations c.4817-2delA and c.A4925G led to aberrant FBN1 mRNA
splicing leading to in frame deletion of exon 39 and in exon 39, respectively. No difference in the mean FBN1 mRNA
level was observed between the entire group of cases and controls, nor between the group of patients with missense
mutations and controls. The mean expression levels associated with premature termination codon (PTC) and splice site
mutations were significantly lower than the levels in patients with missense mutations. A high level of FBN1 mRNA in
the patient with the missense mutation c.G2447T did not segregate with the mutation in three of his first degree
relatives. No association was indicated between the FBN1 transcript level and specific phenotypic manifestations.
Conclusions: Abnormal FBN1 transcripts were indicated in fibroblasts from patients with the splice site mutation
c.4817-2delA and the missense mutation c.A4925G. While the mean FBN1 mRNA expression level in fibroblasts from
patients with splice site and PTC mutations were lower than the mean level in patients with missense mutations and
controls, inter-individual variability was high. The observation that high level of FBN1 mRNA in the patient with the
missense mutation c.G2447T did not segregate with the mutation in the family suggests that variable expression of
the normal FBN1 allele may contribute to explain the variability in FBN1 mRNA level.
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Background
Mutations in FBN1, encoding fibrillin-1 cause Marfan
syndrome (MFS; OMIM #154700) and other heritable
connective tissue disorders, referred to as fibrillinopathies
[1, 2]. The phenotypes caused by FBN1 mutations range
from isolated, minor manifestations to a lethal, neonatal
form of MFS [3, 4]. MFS is an autosomal dominantly
inherited disorder, exhibiting variable clinical expressivity
[5]. Major clinical manifestations are found in the cardio-
vascular (aortic aneurysm with dissection), ocular (ectopia
lentis), and skeletal systems [6].
FBN1 (NM 000138.4) contains 65 exons encoding
profibrillin-1, a 350 kDa glycoprotein that is processed to
fibrillin-1 [7]. Human fibrillin-1 is a main component of
10–12 nm microfibrils located in the extracellular matrix
(ECM) of connective tissues [8]. The protein is modular,
comprising 47 epidermal growth factor-like (EGF) do-
mains, seven transforming growth factor β (TGF-β) bind-
ing protein-like domains, two hybrid domains, and one
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proline-rich region [9]. Forty-three of the 47 EGF do-
mains are calcium binding domains (cbEGF), of which
each is characterised by six cysteine residues, normally
forming three disulphide bonds and a calcium binding
consensus sequence which is involved in protein struc-
ture stabilisation [10].
At the latest update of the UMD-FBN1 mutations data-
base (http://www.umd.be/FBN1/ on 28/08/14), 1847 dif-
ferent mutations and 1096 protein variants have been
identified in FBN1 [www.umd.be/FBN1/] in patients
with MFS and a spectrum of related fibrillinopathies [2].
Missense mutations are the most frequent (55 %) type of
mutations in FBN1, typically affecting cysteins in the
highly conserved cbEGF domains [11]. These mutations
may be associated with increased proteolytic degradation
of fibrillin-1 [12–14]. Twenty-five percent of all known
FBN1 mutations are frameshift or nonsense mutations
leading to premature termination codons (PTC) [15, 16],
potentially generating truncated fibrillin-1 variants that
may assemble into the extracellular microfibrils. Trun-
cated transcripts are usually degraded by the nonsense-
mediated mRNA decay (NMD) mechanism [17], which
would then result in reduced or no expression of trun-
cated fibrillin-1 thus ameliorating negative effects of mi-
crofibrils on ECM. Splice site mutations are also frequent
in MFS [18, 19]. Infrequently, large genomic deletions in-
volving single or multiple exons of the FBN1 gene, as well
as whole FBN1 deletions, have been identified [20–22].
Analyses of fibrillin-1 in cultured dermal fibroblasts from
MFS patients have revealed abnormalities in the synthesis,
secretion, and deposition of fibrillin-1 in the ECM [23–25].
Further, mutant fibrillin-1 may cause abnormal structure
of microfibrils and ECM [26]. Alteration of TGF-β binding
protein like domains may play an additional role in the
pathogenesis of fibrillinopathies, as increased TGF-β sig-
nalling causes deregulation of cytokine function [27, 28].
Two models of MFS pathogenesis have been suggested.
According to the haploinsufficiency model, the pathogen-
esis is based on reduction in the levels of normal fibrillin-1
[22, 29], and according to the dominant-negative model,
mutant fibrillin-1 assembles with molecules of the wild-
type protein, thereby disrupting the function of ECM [30].
We aimed to investigate qualitative and quantitative
effects of 16 mutations in FBN1 on FBN1 mRNA in cul-
tured fibroblasts from 16 MFS patients, comparing with
fibroblasts from individuals with no known connective
tissue disorder.
Methods
Patients and cell cultures
In this study we analyzed the FBN1 mRNA levels in fi-
broblasts from 16 patients with MFS in whom a pre-
sumptive disease-causing mutation has been identified
(Table 1). All patients have been systematically examined
as previously described [31], and satisfied the diagnostic
Ghent criteria from 1996 [32]. The study has been ap-
proved by the Norwegian Regional Ethics Committee
South-East. Fourteen of the presumptive disease-causing
mutations have been reported by us [31]. As controls,
fibroblast cultures from four individuals with no known
connective tissue disorder were established in Depart-
ment of Medical Genetics, Oslo University Hospital, and
two were commercially obtained (BioNordika, Medp-
robe, Lysaker, Norway). In order to study intrafamilial
variability, FBN1 expression levels were determined in
three first degree relatives of one of the patients.
Biopsies from forearm skin were grown in complete
Chang medium (Sigma-Aldrich, St. Louis, MO) from the
same batch, supplemented with L-glutamine, penicillin
and streptomycin (Invitrogen, Carlsbad, CA), and incu-
bated at standard conditions (37° C, 5 % CO2). Fibroblasts
from each individual were cultured in five parallels in a 6-
well plate (seeding wells). Cells were harvested at passage
number 3–5 in late logarithmic growth phase, assessed by
microscopy.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA was extracted from fibroblasts according to the
manufacturer’s instruction, using the RNAqueous Small
Scale Phenol-Free Total RNA isolation kit (Ambion,
Cambridgeshire, UK), and quantified with a NanoDrop
ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE). cDNA synthesis using 600–1200 ng
of RNA was performed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA).
Qualitative analysis of FBN1 mRNA
In order to analyse FBN1 mRNA from patients and con-
trol fibroblast cultures, 10 overlapping cDNA amplicons
covering the whole FBN1 mRNA was PCR amplified using
cDNA specific primers (Additional file 1). Primers were
designed using Primer 3 (www.primer3.sourceforge.net).
PCR fragments were resolved by gel electrophoresis using
ethidium bromide-containing 2 % NuSieve GTG Agarose
gel (Cambrex BioScience, Rockland, ME), which was run
at 70 V for 6 h. PCR products were purified using
AMPure beads (Beckman Coulter Inc, Brea, CA) and se-
quenced directly in both directions by ABI PRISM 3730
Genetic Analyzer (Applied Biosystems).
Quantitative FBN1 mRNA analysis
FBN1 mRNA levels were determined by the 7900 HT Fast
Real-Time PCR System (Applied Biosystems) using TaqMan
Gene Expression Assays for FBN1 (Hs009731199_m1, Ap-
plied Biosystems) and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (Hs99999905_m1, Applied Biosystems).
Real-time PCR was performed in triplicates in a 384-well
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plate and run according to the manufacturer’s recommen-
dation. Negative controls included water and no cDNA
template.
Amplification levels of FBN1 were calculated accord-
ing to the 2-ddCT method [33] including normalization to
the mRNA levels of the house keeping gene GADPH,
and to the FBN1 mRNA levels in the six controls.
Statistical analysis
All results were tested for statistical significance with the
two-tailed, unpaired T- test. P-values <0.05 were consid-
ered statistically significant.
Computer analysis of mutational effect
Consequences of the investigated mutations were pre-
dicted using ALAMUT software (www.interactive-bio-
software.com/alamut/).
Results
Qualitative FBN1 mRNA analysis
Sequence analysis of cDNA from fibroblasts verified the
presence of the eight heterozygous missense mutations,
c.G629A, c.G1027A, c.G2447T, c.T2848C, c.T4348G,
c.T5866C, c.G6388A, and c.G7094A, previously identi-
fied in genomic DNA [31]. Ten overlapping amplicons
covering the FBN1 transcript (Table 1) were analyzed by
gel electrophoresis and appeared normal in these eight pa-
tients (data not shown). Fragment analysis in fibroblasts
from patients with premature termination codons (PTCs)
(c.4269_4270delAC, c.5559delT, and c.T6339A) did not
reveal any aberrant FBN1 transcripts, and sequencing of
the amplicons did not indicate any defects in the mRNA
sequence (data not shown). Fragment analysis of FBN1
mRNA in the patients with splice site mutations (c.3083-
2A >G, c.4211-1G >A, c.4817-2delA, and c.4942 + 2 T >
C) demonstrated an aberrant transcript in the patient with
Table 1 FBN1 genotype, predicted effect, fibroblast FBN1 expression level, and patient characteristics
FBN1 nucleotide
change
Protein change Affected
domain
In silico
predictiona
Type of
mutation
FBN1 mRNA % of
controlsb
Clinical
phenotypec
c.G629A p.Cys210Tyr Hybrid Probably
damaging
Missense 120 ± 35 DOsp
c.G1027A p.Gly343Arg TGF-β1 Possibly
damaging
Missense 219 ± 35 Dos
c.G2447T p.Cys816Phe cbEGF9 Probably
damaging
Missense 212 ± 52 DOCsi
c.T2848C p.Cys950Arg cbEGF10 Probably
damaging
Missense 100 ± 16 DOCsi
c.T4348G p.Cys1450Gly cbEGF21 Probably Missense 169 ± 26 DOoCcSsi
c.T5866C p.Cys1956Arg cbEGF29 damaging Missense 141 ± 24 DOoSi
c.G6388A p.Glu2130Lys cbEGF32 Possibly
damaging
Missense 119 ± 27 DOSsip
c.G7094A p.Cys2365Tyr TGF-β7 Possibly
damaging
Missense 109 ± 18 DOS
Probably
damaging
c.4269_4270delAC p.Pro1424Argfs*6 cbEGF20 Fs, introducing PTC (fs) 88 ± 23 DCcSi
c.5559delT p.Gln1854Lysfs*39 cbEGF27 Fs, introducing PTC (fs) 75 ± 19 DCcs
c.T6339Ad p.Tyr2113X TGF-β6 PTC skip of exon
25
PTC (fs) 53 ± 8 Ds
c.3083-2A > G - Intronic Skip of exon 25 Splice site 51 ± 10 DOoCcSs
c.4211-1G > A - Intronic Skip of exon 34 Splice site 59 ± 11 DOoCcspi
c.4817-2delA p.Ile1607_Asp1648del Intronic Skip of exon 39 Splice site 80 ± 16 DOCcsi
c.4942 + 2 T > C - Intronic Skip of exon 39 Splice site 72 ± 12 DOoCcSsp
c.A4925G p.Thr1643_Asp1648del cbEGF23 CSS Splice site (CSS) 91 ± 17 DOosi
Exons are numbered according to the reference sequence GenBank NM_000138.4. cb, calcium binding
EGF, epidermal growth factor, fs frame shift, PTC premature termination codon, TGF transforming growth factor, CSS cryptic splice site
aIn silico prediction of mutations was obtained using ALAMUT prediction algorithms
bMean FBN1 mRNA expression levels in five parallel wells of fibroblasts from MFS patients compared to controls (n = 6) ± SD. The level in controls was assigned as 100 %
cAffection of organ systems is given according to the original Ghent nosology for the diagnosis MFS. Dura mater: Major criterion: D. Ocular system: Major criterion:
O, Minor manifestations: o. Cardiovascular system: Major criteria: C, Minor criteria: c. Skeletal system: Major manifestations: S, minor manifestations: s. Skin and
integument: Minor criteria implying involvement: i, Pulmonary system: Minor criteria implying involvement: p. dThe mutation was contained in the UMD-FBN1
database (recurrent mutation)
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the c.4817-2delA mutation (Fig. 1a, lane 3) only. Further-
more, the predicted missense mutation, c.A4925G, was
shown by fragment analysis to result in an aberrant
FBN1 transcript (Fig. 1a, lane 4). Sanger sequencing of
the cDNA amplicon of exons 36–44 from the patients
with the c.4817-2delA and c.A4925G mutations showed
two in frame deletions, of c.4925-c.4942 (Fig. 1b) and a
skip of exon 39 (Fig. 1c), respectively. This suggests
that the c.A4925G mutation introduced a cryptic splice
site (CSS), resulting in loss of the terminal 18 nucleo-
tides of exon 39 (Fig. 1d).
Quantitative FBN1 mRNA analysis
Relative FBN1 mRNA levels in fibroblasts from the 16 pa-
tients compared to the level in six controls were deter-
mined by qRT-PCR. The mean FBN1 transcript level in
fibroblasts from all 16 MFS patients were not significantly
different from controls (Fig. 2). Furthermore, there was no
significant difference in the mean FBN1 transcript level in
the group of eight patients with missense mutations, the
group of three patients with PTC, or in the group of five
patients with splice site mutations compared to controls
(Fig. 2a). However, the mean FBN1 transcript level in the
Fig. 1 Localization of mutations in FBN1 and results from qualitative analysis (a) Schematic presentation of FBN1 with the localization of the 16
mutations investigated in this study indicated (b) Analysis of cDNA fragments containing FBN1 exons 36–44 from the patient with c.4817-2delA
(lane 3), c.A4925G (lane 4), and control (lane 2). The fragment size marker is in lane 1. Lanes 3 and 4 show fragments corresponding to the
normal (955 bp) and truncated cDNA fragments of 829 bp and 937 bp from patients with c. 4817-2delA and c. A4925G, respectively. c Fragment
of FBN1 cDNA sequence in patient with 4817 + 2 T > C. d Fragment of FBN1 cDNA sequence in patient with A4925G. e Aberrant splicing resulting
from the mutations, c.4817-2delA and c.A4925G lead to two distinct in frame deletions affecting exon 39 (schematic presentation). Skip of exon
39 (c.4817-4942del) (yellow), was confirmed in the patient with the c.4817-2delA splice site variant, whereas deletion of c.4925-4942 (green) was
identified in the patient with the c.A4925G variant, which likely introduced a cryptic splice site
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two groups of patients with PTC and splice site mutations
were both significantly lower than in the group of patients
with missense mutations (Fig. 2a). Individually, the patients
with the missense mutations c.G1027A and c.G244T
showed significantly higher FBN1 transcript levels than
controls (Additional file 1). To investigate if the high level
in the latter patient could be due to the c.G2447T muta-
tion, we investigated if the high FBN1 mRNA level segre-
gated with the mutation in three first degree relatives; two
with the heterozygous c.G2447T and one without. The
results showed that all four had higher FBN1 mRNA levels
than the mean level in controls, with the highest level in
the index patient and his unaffected sister, who did not
have the heterozygous c.G2447T mutation (Fig. 2b).
Discussion
Qualitative analysis
Sequencing of cDNA from fibroblasts from the patient
with the splice site mutation, c.4942 + 2 T > C did not re-
veal any abnormal FBN1 transcript, indicating that the
transcript affected by this mutation was efficiently elimi-
nated by NMD. The c.4817-2delA caused a skip of exon
39 in the FBN1 transcript demonstrated by gel electro-
phoresis and Sanger sequencing. The fact that the patient
Fig. 2 Results from quantitative analysis of FBN1 mRNA (a) FBN1 transcript levels in fibroblasts from controls (n = 6) and MFS patients with
missense (n = 8), PTC (n = 3), and splice site mutations (n = 5), respectively. Significant differences (p < 0.05) were observed between mean FBN1
transcript levels in patients with missense mutations and patients with PTC mutations and between the levels in patients with missense
mutations and patients with splice site mutations. b FBN1 transcript levels in fibroblasts from the patient with the missense mutation, c.G2447T,
his affected mother and sister, both having the c.G2447T, and his unaffected sister, who tested negative for the mutation, compared to the level
in controls (n = 6). The results are presented as the mean of two experiments with five seeding wells ± SD. The level in controls was assigned
as 100 %
Tjeldhorn et al. BMC Medical Genetics  (2015) 16:113 Page 5 of 8
had a high FBN1 mRNA level suggests that most of the
FBN1 transcripts were rescued from NMD. This result is
consistent with results from other studies, which have in-
dicated that splice site mutations maintaining the reading
frame were not degraded by NMD and therefore did not
cause decreased FBN1 expression [20, 34].
Sequencing of cDNA isolated from the patient with the
mutation c.A4925G showed that the mutation predicted
to cause the missense p.Asp1642Gly in fact caused the
deletion of 18 nucleotides. This finding is explained by
introduction of a CSS, which may cause splicing at a pos-
ition of a transcript where it is usually not spliced [35].
Introduction of CSS has previously been associated with
human diseases, including MFS [36, 37].
Quantitative analysis of FBN1 mRNA expression
FBN1 mRNA expression in MFS patients and controls
We observed high inter-individual variability in FBN1 ex-
pression levels in fibroblasts from individuals with no con-
nective tissue disorder, as well as in MFS patients (Fig. 2a),
similar to results reported by other investigators [38, 39].
Some studies have indicated that FBN1expression may be
affected by the passage number or different growth condi-
tions for the fibroblasts [26]. In the present study the
fibroblasts were cultured under uniform conditions. No
trend was observed with respect to expression level com-
pared to age or gender of the skin biopsy donors, the
source of the control fibroblasts, or if cells were harvested
in different growth phases (data not shown). It has been
suggested that the clinical variability in MFS might be
explained by varying expression levels of both mutant and
normal FBN1 transcripts [38, 40–42]. In line with this,
Hutchinson and co-workers demonstrated that the vari-
able reduction of total FBN1 transcript in three related
individuals carrying a PTC mutation was due to variation
in the expression of the normal FBN1 allele rather than by
NMD of mutant RNA [41]. Further, Aubert and co-
workers recently carried out differential allelic expression
analysis demonstrating reduced FBN1 transcript levels in
patients with PTC and further that 90 % of the transcript
originates from the wild type allele [38]. In the present
study, the similar high levels of FBN1 mRNA in both
affected and non-affected relatives of the patient with the
mutation, c.G2447T indicated that the high level in these
family members was not caused by the mutation (Fig. 2b).
FBN1 expression, type and location of the mutations
In the present study, eight of the 16 mutations were mis-
sense mutations. Our finding of normal or high FBN1
mRNA levels (ranging from 94 to 219 % of controls) in
patients with missense mutations is consistent with find-
ings in other studies [11, 30, 43]. In spite of the high ex-
pression level, the MFS phenotype in the patients with
missense mutations and high FBN1 mRNA level could
not be considered as mild (Additional file 1). An associ-
ation between ectopia lentis and missense mutations in
the cbEGF domain affecting cysteine residues, in the pres-
ence of normal levels of FBN1 mRNA, has been reported
[14]. In the present study, five of the eight missense muta-
tions were located in cbEGF domains of fibrillin-1; four of
them affecting cysteine. All four patients with a mutation
in cbEGF domain affecting cysteine had ectopia lentis, and
their mean FBN1 mRNA level was 156 % of controls. To
our knowledge, few reports exist on the effects of missense
mutations in TGF-β binding protein like domains and hy-
brid domains on FBN1 mRNA expression. Only one mis-
sense mutation in our patients was located in a hybrid
domain (also referred to as a TGF-β binding protein like
domain); in a moderately affected patient with relatively
high FBN1 mRNA level. Two missense mutations were lo-
cated in TGF-β1 and TGF-β7 domains, respectively, and
the clinical phenotypes of the two patients were rather
mild. Their FBN1 mRNA levels differed two-fold, being
109 to 219 % of controls (Additional file 1). Missense mu-
tations may cause disease through a dominant-negative
effect. In line with this, previous studies have demon-
strated that missense mutations in FBN1 caused increased
intracellular misfolded fibrillin-1 [11, 30, 43], which is able
to cause a severe phenotype in the presence of normal or
high FBN1 mRNA level.
In the two MFS patients with the small deletions
c.4269_4270delAC and c.5559delT, the mean FBN1 mRNA
levels were 75 % and 88 % of the level in controls. Both pa-
tients had major affection of the cardiac system (Table 1),
and both deletions were predicted to cause frameshifts
resulting in truncated proteins if the transcripts do not
undergo NMD. Analysis by RT-PCR and gel electro-
phoresis indicated that only the wild type transcripts
were present, indicating NMD. These results are consist-
ent with several studies that have shown that nonsense
and frameshift mutations in FBN1 result in efficient NMD
[16, 43–45]. However, there are also reports on large out-
of-frame deletions of FBN1 that did not cause reduction
of the mRNA levels [21, 22]. Our patient with a nonsense
mutation in exon 51 [c.T6339A (p.Tyr2113X)] was clinic-
ally moderately affected, although the FBN1 mRNA level
was much lower (53 % of the level in controls) than in the
two cases with PTC mutations discussed above (Table 1).
Another nonsense mutation in the same codon has been
reported to cause exon skipping and NMD of the mutant
FBN1 transcript [15]. This indicates that NMD is activated
and is the underlying mechanism causing the low mRNA
level in our patient.
The effect of splice site mutations on mRNA is diffi-
cult to predict [19, 46]. Four splice site mutations were
investigated in this study: the c.4942 + 2 T > C, c.4817-
2delA, c.4211-1G > A, and c.3083-2A > G. In silico ana-
lysis indicated that a skip of exon 39 was likely in the
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first two cases, and we demonstrated this for the c.4817-
2delA. The mutations, c.4942 + 2 T > C and c.4817-2delA
were associated with 72 % and 80 % of FBN1 mRNA ex-
pression compared to controls, respectively, and the pa-
tients were severely affected with several major, including
major cardiovascular, manifestations of MFS (Table 1).
The splice site mutations c.3083-2A >G and c.4211-1G >
A were associated with 51 % and 59 %, respectively, of
FBN1 mRNA expression compared to controls. These pa-
tients were also severely affected (Table 1).
Conclusions
Qualitative analysis of FBN1 mRNA from fibroblasts
from 16 MFS patients and six controls indicated that the
mutations, c.A4925G and c.4817-2delA led to aberrant
splicing resulting in frame deletions in exon 39 or dele-
tion of exon 39, respectively. Quantitative mRNA ana-
lysis revealed considerable variability in FBN1 mRNA
levels in both MFS patients and controls. No difference
in the mean FBN1 mRNA level was observed between
the entire group of cases and controls, nor between the
group of patients with missense mutations and controls,
but the mean expression levels associated with PTC and
splice site mutations were significantly lower than the
levels in controls and patients with missense mutations.
In line with evidence from other studies, the mRNA
levels in fibroblasts derived from four members of one
family suggested that variable expression from the nor-
mal FBN1 transcript may contribute to explain the vari-
ability in FBN1 mRNA level.
Additional file
Additional file 1: Primer sequences used for amplification of
FBN1 cDNA fragments Exons are numbered according to the
cDNA sequence in GenBank (accession number: NM_000138.4).
(DOCX 16 kb)
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